Cognitive dysfunction in multiple sclerosis: current approaches to clinical management

References

• Compston A. The story of Multiple Sclerosis. In: McAlpine's Multiple Sclerosis 3n1 Edition. Compston A, Eber B, Lassmann H, McDonald I, Mettehws B, Wekerle H (Eds). Hartcourt Brace, London, UK, 3–42 (1998).
   Google Scholar
• Weinstock-Guttmann B, Jacobs LD. What is new in the treatment of multiple sclerosis? Drugs 59,401–410 (2000).
   Google Scholar
• Rao SM. Neuropsychological aspects of multiple sclerosis. In:Multiple Sclerosis: Clinical and Pathogenetic Basis. Raine CS, McFarland HF, Tourtellotte WW (Eds), Chapman & Hall, London, UK, 357–362 (1997).
   Google Scholar
• Rao SM, Leo GJ, Ellington L et al. Cognitive dysfunction in MS II: impact on employment and social functioning. Neurology 41, 692–696 (1991).
   PubMed Web of Science ®Google Scholar
• Beatty WW, Blanco CR, Webanks Sl, Paul RII, Hames IKA. Demographic, clinical andcognitive characteristics of MS patients who continue to work. Neural Rehab. 9, 167–173 (1995).
   Google Scholar
• Amato MP, Ponziani G, Pracucci G et al Cognitive impairment in early-onset multiple sclerosis: pattern, predictors and impact on everyday life in a 4-year follow-up. Arch. Neural 52, 168–172 (1995).
   Google Scholar
• Langdon DW, Thompson AJ. Multiple sclerosis: a preliminary study of selected variables affecting rehabilitation outcome. Mutt. Stier 5,94–100 (1999).
   PubMed Web of Science ®Google Scholar
• Kujala P, Portin R, Ruutianen J. Memory deficits and early cognitive deterioration in multiple sclerosis. Acta Neural Scand 93, 329–335 (1996).
   Google Scholar
• Amato MP, Ponziani G, Siracusa G, Sorbi S. Cognitive dysfunction in early-onset multiple sclerosis. A reappraisal after 10 years. Atrh. Neural 58,1602–1606 (2001).
   Google Scholar
• Beatty WW, Monson N. Metamemory in MS. I Clin. Exp. Neuropsychiatry13, 309–327 (1991).
   PubMed Web of Science ®Google Scholar
• Friend KB, Rabin BM, Groninger L, Deluty RII, Bever C, Grattan L. Languagefunctions in patients with multiple sclerosis. Clin. Neuropsychol 13, 78–94 (1999).
   PubMed Web of Science ®Google Scholar
• Kujala P, Portin R, Ruutiainen J. Language functions in incipient cognitive decline in multiple sclerosis. Neural. Sci. 141, 79–86 (1996).
   Google Scholar
• Ivnik RJ. Neuropsychological test performance as a function of the duration of MS-related symptomatology. j Clin. PTchiatry39, 304–307 (1978).
   PubMed Web of Science ®Google Scholar
• Marsh GG. Disability and intellectual function in multiple sclerosis. J. Nerv. Ment. Di s 168, 758–762 (1980).
   PubMedGoogle Scholar
• Rao SM, Glatt S, Hammeke TA et al. Chronic progressive multiple sclerosis: relationship between cerebral ventricular size and neuropsychological impairment. Alrh. Neural. 42, 678–682 (1985).
   Google Scholar
• Heaton RK, Nelson LM, Thompson DS et al. Neuropsychological findings in relapsing-remitting and chronic-progressive multiple sclerosis. J. Consult. Clin. Bychol 53, 103–110 (1985).
   PubMed Web of Science ®Google Scholar
• Rao SM, Hammeke TA, McQuillen MP et al. Memory disturbance in chronic-progressive multiple sclerosis. Arch. Neural. 41, 625–631 (1984).
   PubMed Web of Science ®Google Scholar
• Thornton AE, Raz N. Memory impairment in multiple sclerosis: a quantitative review. Neuropsychologyll, 357–366 (1997).
   Google Scholar
• Feinstein A, Kartsounis LD, Miller DH et al Clinically isolated lesions of the type seen in multiple sclerosis: a cognitive, psychiatric and MRI follow-up study. Neural. Neurosurg. Psychiatry 55, 869–876 (1992).
   PubMed Web of Science ®Google Scholar
• Feinstein A, Ron M, Thompson A. A serial study of psychometric and magnetic resonance imaging changes in multiple sclerosis. Brain 116, 569–602 (1993).
   Google Scholar
• Lyon-Caen O, Jouvent R, Hauser S et al Cognitive function in recent-onset demyelinating diseases. Arch. Neural 43, 1138–1141 (1986).
   PubMed Web of Science ®Google Scholar
• Grant CM, McDonald WI, Trimble MR et al. Deficient learning and memory in early and middle phases of multiple sclerosis.' Neural. Neurosurg. Pwchiati y47, 250–255 (1984).
   PubMed Web of Science ®Google Scholar
• McIntosh-Michaelis SA, Roberts MH, Wilkinson SM et al The prevalence of cognitive impairment in a community survey of multiple sclerosis. BE J. Clin. Psycho]: 30, 333–348 (1991).
   Google Scholar
• Kurtzke JE Rating neurological impairment in multiple sclerosis: an expanded disability status scale (ED55). Neurology33, 1444–1452 (1983).
   PubMed Web of Science ®Google Scholar
• Amato MP, Ponziani G. Quantification of impairment in MS: discussion of the scales in use. Mult. &ler 5(4), 216–219 (1999).
   Google Scholar
• Grossman M, Armstrong C, Onishi K et al Patterns of cognitive impairment in relapsing-remitting and chronic-progressive multiple sclerosis. Neuropsych. Neuropsychol &hay. Neural. 7, 194–210 (1994).
   Google Scholar
• Filippi M, Alberoni M, Martinelli V et al Influence of clinical variables on neuropsychological performance in multiple sclerosis. Eur. Neural. 34, 324–328 (1994).
   PubMed Web of Science ®Google Scholar
• Nocentini U, Rossini PM, Carlesimo GA et al Patterns of cognitive impairment in secondary progressive stable phase of multiple sclerosis: correlations with MRI findings. Eur. Neural. 45, 11–18 (2001).
   PubMed Web of Science ®Google Scholar
• Roelcke U, Kappos L, Lechner-Scott J et al Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study. Neurology 48, 1566–1571 (1997).
   PubMed Web of Science ®Google Scholar
• Rao SM, Leo GJ, Haughton VM et al. Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. Neurology 39, 161–166 (1989).
   PubMed Web of Science ®Google Scholar
• Huber SJ, Bornstein RA, Rammohan KW, Christy JA, Chakeres DW, McGhee RB. Magnetic resonance imaging correlates of neuropsychological impairment analysis in multiple sclerosis. Arch. Neural. 54, 1018–1025 (1997).
   PubMedGoogle Scholar
• Rovaris M, Filippi M, Falautano M et al Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis. Neumlogy6, 1601–1608 (1998).
   Google Scholar
• Hohol MJ, Guttmann CRG, Orav J et al. Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis. Arch. Neurol 54, 1018–1025 (1997).
   PubMedGoogle Scholar
• Mariani C, Farina E, Cappa SF et al. Neuropsychological assessment in multiple sclerosis: a follow-up study with magnetic resonance imaging. J. Neural. 238, 395–400 (1991).
   PubMed Web of Science ®Google Scholar
• Comi G, Filippi M, Martinelli V et al Brain magnetic resonance imaging correlates of cognitive impairment in multiple sclerosis. J. Neural. Sci. 115 (Suppl. 5), 66–73 (1993).
   Google Scholar
• Camp SJ, Stevenson VL, Thompson AJ et al. Cognitive function in primary progressive and transitional progressive multiple sclerosis: a controlled study with MRI correlates. Blain 122, 1341–1348 (1999).
   Google Scholar
• Clark CM, James G, Li D, Oger J, Paty D, Klonoff H. Ventricular size, cognitive function and depression in patients with multiple sclerosis. Can. J. Neural. Sci 19, 352–356 (1992).
   PubMedGoogle Scholar
• Anzola GP, Bevilacqua L, Cappa SF etal. Neuropsychological assessment in patients with relapsing-remitting multiple sclerosis and mild functional impairment: correlation with magnetic resonance imaging. J. Neumsurg Psychiatry53, 142–145 (1990).
   Google Scholar
• Maurelli M, Marchioni E, Cerretano R et al Neuropsychological assessment in MS: clinical, neurophysiological and neuroradiological relationships. Acta Neural. Scam 86, 124–128 (1992).
   PubMed Web of Science ®Google Scholar
• Swirsky-Sacchetti T, Mitchell DR, Seward J et al Neuropsychological and structural brain lesions in multiple sclerosis: a regional analysis. Neurology 42, 1291–1295 (1992).
   PubMed Web of Science ®Google Scholar
• Damian MS, Schilling G, Bachmann G, Simon C, Stoppler S, Dorndorf W. White matter lesions and cognitive deficits: relevance of lesion pattern? Acta Neural. Scam/. 90, 430–436 (1994).
   Google Scholar
• Miki Y, Grossman RI, Udupa JK et al Isolated U-fiber involvement in MS: preliminary observations. Neurology50, 1301–1306 (1998).
   PubMedGoogle Scholar
• Foong J, Rozewicz L, Davie CA, Thompson AJ, Miller DH, Ron MA. Correlates of executive function in multiple sclerosis: the use of magnetic resonance spectroscopy as an index of focal pathology. I Aiumpsychiatry Clin. Aill1E6Ci. 11, 45–50 (1999).
   Google Scholar
• Filippi M, Tortorella C, Rovaris M et al Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis.' Neural. Neurosurg. Bychiatry68, 157–161 (2000).
   PubMed Web of Science ®Google Scholar
• J Folstein MF, Folstein SE, McHugh PR. Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. Psychiatr Res. 12(3), 189–198 (1975).
   Google Scholar
• Beatty WW Goodkin DE. Screening for cognitive impairment in multiple sclerosis: an evaluation of the Mini-Mental State Examination. Arch. New& 47,297–301 (1990).
   Google Scholar
• Swirsky-Sacchetti T, Field HL et al The sensivity of the Mini-Mental State Exam in the white matter dementia of multiple sclerosis. J. Clin. Psychol. 48,779–786 (1992).
   PubMed Web of Science ®Google Scholar
• Beatty WW Paul RII, Wilbanks SL, Hames IKA, Blanco CR, Goodkin DE. Identifying multiple sclerosis patients with mild or global cognitive impairment using the Screening Examination for Cognitive Impairment (SEFCI) . Neurology 45 (4), 718–723 (1995).
   PubMedGoogle Scholar
• Rao SM and the Cognitive Function Study Group of the National Multiple Sclerosis Society. A manual for the Brief Repeatable Battery of Neuropsychological Tests in multiple sclerosis. Medical College of Wisconsin, Milwaukee, WI, USA (1990).
   Google Scholar
• Solari A, Mancuso L, Motta A, Mendozzi L, Serrati C. Comparison of two brief neuropsychological batteries in people with multiple sclerosis. Mutt. Scler. 8,169–176 (2002).
   Google Scholar
• Aupperle RL, Beatty WW, Shelton FdeNAP, Gontkovsky ST Three screening batteries to detect cognitive impairment in multiple sclerosis. Mutt. Scler. (In press).
   Google Scholar
• Basso MR, Beason-Hazen S, Lynn J, Rammohan K, Bornstein RA. Screening for cognitive dysfunction in multiple sclerosis. Arch. Neuml. 53(10), 980–984 (1996).
   PubMedGoogle Scholar
• Peyser JM, Rao SM, LaRocca NG, Kaplan E. Guidelines for neuropsychological research in multiple sclerosis. Arch. Neural 47,94–97 (1990).
   PubMed Web of Science ®Google Scholar
• Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporin in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. Ann. Neural 27, 591–605 (1990).
   PubMedGoogle Scholar
• Godkin DE, Fisher JS.Treatment of multiple sclerosis with methtrexate. In: Treatment of Multiple Sclerosis: Advanced in Trial Design, Results and future prospectives. Goodkin DE, Rudick RA (Eds), Springer, London, UK, 251–287 (1996).
   Google Scholar
• The IFN-I3 Multiple Sclerosis Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I.Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43(4), 655–661 (1993).
   Google Scholar
• Pliskin NH, Hamer DP, Goldstein DS, Towle VL, Reder AT, Noronha A, Arnason BG. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-lb. Neurology 47 (6), 1463–1468 (1996) .
   PubMed Web of Science ®Google Scholar
• •Study is interest, although flawed, since it is the first trial to assess with an experimental design the possible efficacy of IFNI3-lb on cognitive outcomes.
   Google Scholar
• Johnson IKP, Brooks BR, Cohen JA etal. Co-polymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a Phase III multicenter, double-blind placebo-controlled trial. The co-polymer 1 Multiple Sclerosis Study Group. Neurology45 (7), 1268–1276 (1995).
   Google Scholar
• Weinstein A, Schwid SI, Schiffer RB, McDermott MP, Giang DW, Goodman AD. Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Atch. Neural 56(3), 319–324 (1999).
   PubMedGoogle Scholar
• ••Pivotal Phase III trial focusing on theeffects of glatirarner on cognitive function.
   Google Scholar
• Mariani C, Farina E, Cappa SF et al Neuropsychological assessment in multiple sclerosis: a follow-up study with magnetic resonance irnaging.j Neural 238(7), 395–400 (1991).
   PubMedGoogle Scholar
• Jacobs LD, Cookfair DL, Rudick RA et al Intramuscular interferon beta-la for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neural 39(3), 285–294 (1996).
   Google Scholar
• Fischer JS, Priore RL, Jacobs LD et al Neuropsychological effects of interferon beta-la in relapsing multiple sclerosis. Multiple Sclerosis collaborative Research Group. Ann. Neural 48(6), 885–892 (2000).
   Google Scholar
• ••Pivotal Phase III trial demonstrating aclear effect of IFNI3-la therapy on cognitive measures.
   Google Scholar
• Cohen RA, Fisher M. Amantadine treatment of fatigue associated with multiple sclerosis. Arch. Neural 46(6), 676–680 (1989).
   PubMedGoogle Scholar
• Geisler MW Sliwinski M, Coyle PK, Masur DM, Doscher C, Krupp LB. The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Arch. Neural 53(2), 185–188 (1996).
   PubMedGoogle Scholar
• Smits RC, Emmen 1111, Bertelsmann FVV, Kulig BM, van Loenen AC, Polman CH. The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study. Neurology44(9), 1701–1705 (1994).
   Google Scholar
• Rossini PM, Pasqualetti P, Pozzilli C et al Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult. Scler 7(6), 354–358 (2001).
   Google Scholar
• Bever CT Jr, Anderson PA, Leslie J et al Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial. Neumlogy 47(6), 1457–1462 (1996).
   Google Scholar
• Greene YM, Tariot PN, Wishart H etal. A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments. J. Clin. Rychopharmacol 20(3), 350–356 (2000).
   Google Scholar
• Mohr DC, Cox D. Multiple sclerosis: empirical literature for the clinical health psychologist. J. Clin. Psychol. 57(4), 479–499 (2001).
   Google Scholar
• Allen DN, Goldstein G, Heyman RA, Rondinelli T Teaching memory strategies to persons with multiple sclerosis. J. Rehabil Res. Dev 35(4), 405–410 (1998).
   Google Scholar
• Canellopoulou M, Richardson JTE. The role of executive function in imagery mnemonics: evidence from multiple sclerosis. Neuropsychology36,1181–1188 (1998).
   Google Scholar
• Mohr DC, Dick LP, Russo D etal. The psychosocial impact of multiple sclerosis: exploring the patient's perspective. Health Psychol. 18(4), 376–382 (1999).
   PubMed Web of Science ®Google Scholar
• Prosiegel M, Michael C. Neuropsychology and multiple sclerosis: diagnostic and rehabilitative approaches. J. Neural Sci 115\(Suppl. 5), 51–54 (1993).
   Google Scholar
• Jonsson A, Korfitzen EM, Heltberg A, Ravnborg MET, Byskov-Ottosen E. Effects of neuropsychological treatment in patients with multiple sclerosis. Acta Neural Scand. 88(6), 394–400 (1993).
   PubMedGoogle Scholar
• Plohmann AM, Kappos L, Ammann W et al. Computer assisted retraining of attentional impairments in patients with multiple sclerosis. J. Neural. Neurosurg. Psychiatry 64(4), 455–462 (1998).
   Google Scholar
• •Demonstrates the effectiveness of cognitive rehabilitation techniques.
   Google Scholar
• Rodgers D, Khoo K, MacEachen M, Oven M, Beatty WW Cognitive therapy for multiple sclerosis: a preliminary study. Altern. Ther. Health Med. 2(5), 70–74 (1996).
   Google Scholar
• Benedict RII, Shapiro A, Priore R, Miller C, Munschauer F, Jacobs L. Neuropsychological counseling improves social behavior in cognitively-impaired multiple sclerosis patients. Mult. Scler 6(6), 391–396 (2000).
   PubMedGoogle Scholar
• Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN. Efficacy and safety of modafinil (Provigi0 for the treatment of fatigue in multiple sclerosis: a two centre Phase 2 study. Neural. Neurosurg. Psychiaby 72(2), 179–183 (2002).
   Google Scholar